Table 3. Summary of the meta-analysis results for MDM2 SNP309 and TP53 Arg72Pro polymorphisms and HCC risk.
| Comparison | Population | No. of studies | Test of association | Mode | Test of heterogeneity | ||||
| OR | 95% CI | P Value | χ2 | PQ | I2 | ||||
| MDM2 SNP309 | |||||||||
| G vs. T | Overall | 10 | 1.371 | 1.153–1.631 | 0.000 | R | 39.11 | 0.000 | 77.0 |
| Caucasian | 2 | 1.987 | 1.488–2.653 | 0.000 | F | 0.01 | 0.907 | 0.0 | |
| Asian | 7 | 1.249 | 1.039–1.501 | 0.018 | R | 26.58 | 0.000 | 77.4 | |
| African | 1 | 1.569 | 1.090–2.258 | 0.015 | – | – | – | – | |
| HBV positive | 4 | 1.207 | 0.933–1.563 | 0.153 | R | 16.88 | 0.001 | 82.2 | |
| HCV positive | 3 | 1.481 | 1.245–1.761 | 0.000 | F | 2.67 | 0.263 | 25.1 | |
| High quality studies | 5 | 1.467 | 1.284–1.674 | 0.000 | F | 3.47 | 0.483 | 0.0 | |
| GG vs. TT | Overall | 10 | 1.831 | 1.300–2.579 | 0.001 | R | 34.56 | 0.000 | 74.0 |
| Caucasian | 2 | 3.604 | 1.991–6.524 | 0.000 | F | 0.00 | 0.974 | 0.0 | |
| Asian | 7 | 1.539 | 1.070–2.212 | 0.020 | R | 23.98 | 0.001 | 75.0 | |
| African | 1 | 2.604 | 1.079–6.280 | 0.033 | – | – | – | – | |
| HBV positive | 4 | 1.416 | 0.864–2.322 | 0.168 | R | 14.82 | 0.002 | 79.8 | |
| HCV positive | 3 | 2.198 | 1.542–3.134 | 0.000 | F | 1.65 | 0.437 | 0.0 | |
| High quality studies | 5 | 2.096 | 1.567–2.803 | 0.000 | F | 2.39 | 0.665 | 0.0 | |
| TG vs. TT | Overall | 10 | 1.416 | 1.126–1.780 | 0.003 | R | 20.48 | 0.015 | 56.1 |
| Caucasian | 2 | 2.433 | 1.509–3.922 | 0.000 | F | 0.26 | 0.613 | 0.0 | |
| Asian | 7 | 1.242 | 0.989–1.560 | 0.062 | R | 11.32 | 0.079 | 47.0 | |
| African | 1 | 1.590 | 0.958–2.641 | 0.073 | – | – | – | – | |
| HBV positive | 4 | 1.145 | 0.938–1.398 | 0.184 | F | 5.60 | 0.133 | 46.4 | |
| HCV positive | 3 | 1.759 | 1.280–2.418 | 0.001 | F | 1.90 | 0.387 | 0.0 | |
| High quality studies | 5 | 1.571 | 1.225–2.014 | 0.000 | F | 2.97 | 0.562 | 0.0 | |
| GG vs. TG+TT | Overall | 10 | 1.398 | 1.148–1.703 | 0.001 | R | 19.51 | 0.021 | 53.9 |
| Caucasian | 2 | 2.112 | 1.271–3.507 | 0.004 | F | 0.10 | 0.755 | 0.0 | |
| Asian | 7 | 1.298 | 1.053–1.601 | 0.015 | R | 1.20 | 0.977 | 0.0 | |
| African | 1 | 2.081 | 0.897–4.827 | 0.088 | – | – | – | – | |
| HBV positive | 4 | 1.244 | 0.932–1.661 | 0.139 | R | 9.51 | 0.023 | 68.5 | |
| HCV positive | 3 | 1.507 | 1.147–1.980 | 0.003 | F | 0.94 | 0.626 | 0.0 | |
| High quality studies | 5 | 1.564 | 1.281–1.908 | 0.000 | F | 1.70 | 0.791 | 0.0 | |
| GG+TG vs. TT | Overall | 10 | 1.577 | 1.209–2.058 | 0.001 | R | 31.08 | 0.000 | 71.0 |
| Caucasian | 2 | 2.734 | 1.743–4.289 | 0.000 | F | 0.14 | 0.704 | 0.0 | |
| Asian | 7 | 1.377 | 1.036–1.830 | 0.028 | R | 19.71 | 0.003 | 69.6 | |
| African | 1 | 1.719 | 1.058–2.794 | 0.029 | – | – | – | – | |
| HBV positive | 4 | 1.289 | 0.883–1.881 | 0.188 | R | 11.31 | 0.010 | 73.5 | |
| HCV positive | 3 | 1.926 | 1.426–2.601 | 0.000 | F | 2.09 | 0.352 | 4.2 | |
| High quality studies | 5 | 1.765 | 1.394–2.235 | 0.000 | F | 2.70 | 0.610 | 0.0 | |
| p53 Arg72Pro | |||||||||
| Pro vs. Arg | Overall | 14 | 1.045 | 0.938–1.164 | 0.424 | R | 38.51 | 0.000 | 66.2 |
| Caucasian | 4 | 1.105 | 0.897–1.362 | 0.347 | F | 4.43 | 0.218 | 32.3 | |
| Asian | 9 | 1.017 | 0.899–1.151 | 0.788 | R | 30.97 | 0.000 | 74.2 | |
| African | 1 | 1.330 | 0.911–1.941 | 0.140 | – | – | – | – | |
| HBV positive | 7 | 1.041 | 0.856–1.267 | 0.686 | R | 27.03 | 0.000 | 77.8 | |
| HCV positive | 3 | 0.957 | 0.721–1.270 | 0.759 | F | 0.32 | 0.851 | 0.0 | |
| High quality studies | 7 | 1.106 | 0.964–1.270 | 0.151 | R | 26.86 | 0.000 | 77.7 | |
| ProPro vs. ArgArg | Overall | 14 | 1.132 | 0.887–1.446 | 0.319 | R | 43.70 | 0.000 | 70.2 |
| Caucasian | 4 | 1.454 | 0.864–2.446 | 0.159 | F | 4.85 | 0.183 | 38.2 | |
| Asian | 9 | 1.044 | 0.805–1.356 | 0.744 | R | 33.12 | 0.000 | 75.8 | |
| African | 1 | 2.304 | 0.954–5.234 | 0.046 | – | – | – | – | |
| HBV positive | 7 | 1.159 | 0.751–1.789 | 0.506 | R | 31.95 | 0.000 | 81.2 | |
| HCV positive | 3 | 1.169 | 0.606–2.255 | 0.640 | F | 0.43 | 0.805 | 0.0 | |
| High quality studies | 7 | 1.285 | 0.934–1.768 | 0.123 | R | 33.80 | 0.000 | 82.2 | |
| ArgPro vs. ArgArg | Overall | 14 | 1.023 | 0.938–1.114 | 0.611 | F | 17.77 | 0.166 | 26.9 |
| Caucasian | 4 | 0.984 | 0.743–1.302 | 0.907 | F | 3.82 | 0.282 | 21.5 | |
| Asian | 9 | 1.017 | 0.889–1.162 | 0.810 | R | 13.83 | 0.086 | 42.2 | |
| African | 1 | 0.973 | 0.576–1.647 | 0.920 | – | – | – | – | |
| HBV positive | 7 | 0.957 | 0.845–1.083 | 0.483 | F | 10.38 | 0.110 | 42.2 | |
| HCV positive | 3 | 0.802 | 0.545–1.180 | 0.262 | F | 0.04 | 0.980 | 0.0 | |
| High quality studies | 7 | 1.061 | 0.964–1.167 | 0.228 | F | 4.64 | 0.591 | 0.0 | |
| ProPro vs. ArgPro+ArgArg | Overall | 14 | 1.129 | 0.909–1.402 | 0.273 | R | 43.69 | 0.000 | 70.2 |
| Caucasian | 4 | 1.561 | 0.946–2.574 | 0.081 | F | 5.36 | 0.148 | 44.0 | |
| Asian | 9 | 1.041 | 0.835–1.297 | 0.721 | R | 31.06 | 0.000 | 74.2 | |
| African | 1 | 2.327 | 0.949–5.162 | 0.038 | – | – | – | – | |
| HBV positive | 7 | 1.202 | 0.812–1.780 | 0.357 | R | 32.67 | 0.000 | 81.6 | |
| HCV positive | 3 | 1.291 | 0.684–2.437 | 0.430 | F | 0.43 | 0.807 | 0.0 | |
| High quality studies | 7 | 1.223 | 0.915–1.635 | 0.174 | R | 37.19 | 0.000 | 83.9 | |
| ProPro+ArgPro vs. ArgArg | Overall | 14 | 1.032 | 0.912–1.167 | 0.619 | R | 23.41 | 0.037 | 44.5 |
| Caucasian | 4 | 1.040 | 0.795–1.361 | 0.774 | F | 3.69 | 0.297 | 18.7 | |
| Asian | 9 | 1.020 | 0.878–1.184 | 0.799 | R | 19.36 | 0.013 | 58.7 | |
| African | 1 | 1.174. | 0.725–1.900 | 0.515 | – | – | – | – | |
| HBV positive | 7 | 0.980 | 0.790–1.215 | 0.852 | R | 14.70 | 0.023 | 59.2 | |
| HCV positive | 3 | 0.855 | 0.594–1.233 | 0.402 | F | 0.14 | 0.932 | 0.0 | |
| High quality studies | 7 | 1.056 | 0.964–1.156 | 0.240 | F | 9.70 | 0.138 | 38.1 | |
OR, odds ratio; CI, confidence intervals; R, random effects model; F, fixed effects model; PB, Population–based; HB, Hospital–based.